Home    Back

Tiratricol    (DrugBank: Tiratricol)

2 diseases
IDDisease name (Link within this page)Number of trials
78Hypopituitarism1
139Congenital cerebral hypomyelination6

78. Hypopituitarism    [ 462 clinical trials,   346 drugs,   (DrugBank: 45 drugs),   41 drug target genes,   80 drug target pathways]
Searched query = "Hypopituitarism", "Anterior pituitary hypothyroidism", "Syndrome of abnormal secretion of gonadotropin", "Hyposecretion of gonadotropins", "Adrenocorticotropic hormone deficiency", "ACTH deficiency", "Thyroid-stimulating hormone deficiency", "TSH deficiency", "Growth hormone deficiency", "GH deficiency", "GHD", "CGHD", "AGHD", "Prolactin deficiency", "PRL deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 462 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2019-003370-35-GB
(EUCTR)		28/02/202007/01/2020Tiratricol treatment of children with Monocarboxylate Transporter 8 deficiency: Triac Trial IITiratricol treatment of children with Monocarboxylate Transporter 8 deficiency: Triac Trial II - Triac Trial II Monocarboxylate Transporter 8 (MCT8) deficiency
MedDRA version: 20.0;Level: PT;Classification code 10078564;Term: Thyroid stimulating hormone deficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]		Product Name: Emcitate
INN or Proposed INN: TIRATRICOL
Product Name: Emcitate
INN or Proposed INN: TIRATRICOL		Rare Thyroid Therapeutics International ABNULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes		22Phase 2United States;France;Czech Republic;Netherlands;Germany;Italy;United Kingdom

139. Congenital cerebral hypomyelination    [ 10 clinical trials,   7 drugs,   (DrugBank: 2 drugs),   2 drug target genes,   2 drug target pathways]
Searched query = "Congenital cerebral hypomyelination", "Congenital cerebral white matter aplasia", "Pelizaeus-Merzbacher disease", "Pelizaeus-Merzbacher-like disease 1", "Pelizaeus-Merzbacher-like disease type 1", "Hypomyelination with atrophy of the basal ganglia and cerebellum", "18q-syndrome", "Chromosome 18q deletion syndrome", "Allan-Herndon-Dudley syndrome", "Mitochondrial Hsp60 chaperonopathy", "Salla disease", "Diffuse cerebral hypomyelination with cerebellar atrophy and hypoplasia of the corpus callosum", "Hypomyelination and congenital cataract", "Ataxia, delayed dentition, and hypomyelination", "Peripheral demyelinating neuropathy", "Central dysmyelinating leukodystrophy", "Waardenburg syndrome", "Hirschsprung disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
6 / 10 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02396459
(ClinicalTrials.gov)		March 20207/3/2015Triac Trial II in MCT8 Deficiency PatientsTiratricol Treatment of Children With Monocarboxylate Transporter 8 Deficiency: Triac Trial IIAllan-Herndon-Dudley SyndromeDrug: TriacRare Thyroid Therapeutics International ABErasmus Medical CenterNot yet recruitingN/A30 MonthsMale18Phase 2Netherlands
2EUCTR2014-000178-20-CZ
(EUCTR)		04/02/201623/06/2015Therapy of MCT8 patients with the thyroid hormone analog Triac.Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. - Triac Trial in MCT8 patients This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic clinical phenotype of severe psychomotor retardation due to local hypothyroidism in the brain, in combination with high serum T3 and high normal serum TSH levels that lead to local hyperthyroidism in tissues that do not dependent on MCT8, resulting in tachycardia, low body weight and muscle wasting.;Therapeutic area: Diseases [C] - Hormonal diseases [C19]Trade Name: Téatrois (Tiratricol)
Product Name: Téatrois		Erasmus Medical CentreNULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes		40Phase 2Czech Republic;Belgium;Germany;Italy
3EUCTR2014-000178-20-IT
(EUCTR)		01/02/201616/10/2015Therapy of MCT8 patients with the thyroid hormone analog Triac.Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. - Triac Trial in MCT8 patients This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic clinical phenotype of severe psychomotor retardation due to local hypothyroidism in the brain, in combination with high serum T3 and high normal serum TSH levels that lead to local hyperthyroidism in tissues that do not dependent on MCT8, resulting in tachycardia, low body weight and muscle wasting.;Therapeutic area: Diseases [C] - Hormonal diseases [C19]Trade Name: Téatrois (Tiratricol)
Product Name: Téatrois		Erasmus Medical CentreNULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes		40Phase 2Germany;Italy
4EUCTR2014-000178-20-FR
(EUCTR)		14/01/201614/12/2015Therapy of MCT8 patients with the thyroid hormone analog Triac.Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. - Triac Trial in MCT8 patients This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic clinical phenotype of severe psychomotor retardation due to local hypothyroidism in the brain, in combination with high serum T3 and high normal serum TSH levels that lead to local hyperthyroidism in tissues that do not dependent on MCT8, resulting in tachycardia, low body weight and muscle wasting.;Therapeutic area: Diseases [C] - Hormonal diseases [C19]Trade Name: Téatrois (Tiratricol)
Product Name: Téatrois		Erasmus Medical CentreCentre Hospitalier de ToulouseNot RecruitingFemale: no
Male: yes		40Phase 2France;Czech Republic;Canada;Belgium;Australia;South Africa;Germany;Italy
5EUCTR2014-000178-20-BE
(EUCTR)		12/08/201522/06/2015Therapy of MCT8 patients with the thyroid hormone analog Triac.Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. - Triac Trial in MCT8 patients This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic clinical phenotype of severe psychomotor retardation due to local hypothyroidism in the brain, in combination with high serum T3 and high normal serum TSH levels that lead to local hyperthyroidism in tissues that do not dependent on MCT8, resulting in tachycardia, low body weight and muscle wasting.;Therapeutic area: Diseases [C] - Hormonal diseases [C19]Trade Name: Téatrois (Tiratricol)
Product Name: Téatrois		Erasmus Medical CentreNULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes		40Phase 2Canada;Belgium;Australia;Chile;South Africa;Germany;Italy
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6EUCTR2014-000178-20-DE
(EUCTR)		05/10/2015Therapy of MCT8 patients with the thyroid hormone analog Triac.Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. - Triac Trial in MCT8 patients This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic clinical phenotype of severe psychomotor retardation due to local hypothyroidism in the brain, in combination with high serum T3 and high normal serum TSH levels that lead to local hyperthyroidism in tissues that do not dependent on MCT8, resulting in tachycardia, low body weight and muscle wasting.;Therapeutic area: Diseases [C] - Hormonal diseases [C19]Trade Name: Téatrois (Tiratricol)
Product Name: Téatrois
INN or Proposed INN: Tiratricol		Erasmus Medical CentreNULLNot RecruitingFemale: no
Male: yes		40Phase 2France;Czech Republic;Canada;Belgium;Australia;Israel;South Africa;Germany;Italy

Back to top